Prosecution Insights
Last updated: November 13, 2026
Application No. 18/400,189

Rapid Onset Therapeutic Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Compounds and Methods for Stroke medication co-administration

Non-Final OA §103§112
Filed
Dec 29, 2023
Priority
Dec 30, 2022 — provisional 63/478,103
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
American Ketone Therapeutics LLC
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
109 granted / 144 resolved
+15.7% vs TC avg
Strong +37% interview lift
Without
With
+36.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
66 currently pending
Career history
179
Total Applications
across all art units

Office Action

§103 §112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-16 are pending. Claims 11-16 are withdrawn. Claims 1-10 are rejected. Information Disclosure Statement The Information Disclosure Statement submitted on 12/29/2023 was considered by the Examiner. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-10, in the reply filed on 4/24/2026 is acknowledged. Claims 11-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Specification The disclosure is objected to because of the following informalities: On p. 11, line 10, the specification refers to “the depressive symptoms”. Examiner recommends changing this to “the stroke systems” to be consistent with the claims and the correct application. Appropriate correction is required. Claim Objections Claim 1 is objected to because of the following informalities: Line 2: Replace “Assessing” with “assessing”; Line 3: Replace “Administering” with “administering”; Line 4: Replace “Evaluating” with “evaluating”; Line 5: Replace “Readministering” with “readministering”. Appropriate correction is required. Claim 2 is objected to because of the following informalities: Line 1: Replace “Administering” with “administering”. Appropriate correction is required. Claim 3 is objected to because of the following informalities: Line 1: Replace “Assessing” with “assessing”. Appropriate correction is required. Claim 4 is objected to because of the following informalities: Line 2: Replace “Administering” with “administering”; Line 3: Replace “Free” with “free”. Appropriate correction is required. Claim 5 is objected to because of the following informalities: Line 2: Replace “Administering” with “administering”; Line 3: Replace “Free” with “free”. Appropriate correction is required. Claim 6 is objected to because of the following informalities: Line 2: Replace “Administering” with “administering”; Line 3: Replace “Free” with “free”. Appropriate correction is required. Claim 7 is objected to because of the following informalities: Line 1: Replace “Readministering” with “readministering”. Appropriate correction is required. Claim 8 is objected to because of the following informalities: Lines 1 and 2: Replace “Readministering” with “readministering”; Lines 1 and 2 repeat the same words in duplicate: “wherein the Readministering free D-BetaHydroxyButyric Acid”; one should be deleted. Appropriate correction is required. Claim 10 is objected to because of the following informalities: Line 1: Replace “Readministering” with “readministering”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites four different steps, not requiring any particular order. Only one of the four steps (evaluating the stroke symptoms of a subject in need) refer to whom the method applies to. The other three steps (assessing, administering and readministering) do not require any particular subject for which to apply the method and it is unclear if said three steps apply to the same “subject in need” as referred to above. To overcome this deficiency, Examiner recommends clarifying the recipient of each step. Claim 3 recites: “assessing spinal ischemia symptoms” but does not indicate to which subject. It is unclear if said step applies to the same “subject in need” as referred to above within claim 1. To overcome this deficiency, Examiner recommends clarifying the recipient of claim 3. The term “substantially” in claim 8 is a relative term which renders the claim indefinite. The term “substantially” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Consequently, the metes and bounds of the term following substantially, “mitigated” cannot fully be ascertained. Claims 2, 4-7 and 9-10 are additionally rejected for ultimately depending from claim 1 and failing to remedy its deficiencies. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cahill (Annu. Rev. Nutr. 2006, 26: 1-22- disclosed on 12/29/2023 IDS), in view of Veech et al. (US20060280721), and further in view of Yang et al. (frontiers in Neurology, 2019, 10: 585, 1-11). Determining the scope and contents of the prior art. (See MPEP § 2141.01) Cahill teaches the following: “Due to its use by brain, D-B-hydroxybutyric acid not only has permitted man to survive prolonged starvation, but also may have therapeutic potential owing to its greater efficiency in providing cellular energy in ischemic states such as stroke….” (see p. 1, abstract). Cahill fails to teach specifically assessing ketone levels, assessing/evaluating stroke systems, nor the administration of a therapeutic amount between 5 and 30 grams of free D-BetaHydroxyButyric Acid. Veech discloses nutritional supplements and therapeutic compositions comprising (R )-3-hydroxybutyrate (ketone body that differs from the instant D-betahydroxybutyric acid by one proton and alternates forms in acidic environments) derivatives (see title). Additionally, Veech discloses successful therapeutic effects of administration of sodium-3-hydroxybutyrate by Van Hove et al. (see para. [0090]). “The therapeutic blood ketone body concentrations observed by Van Hove et al., can be produced in a 70 kilogram man using from about 5 to about 70 grams per day of (R )-3-hydroxybutyrate equivalents” (see para. [0091]). Veech additionally discloses that diseases, such as ischemia and spinal cord trauma, caused by damage due to excessive free radical production, can be treated using the (R )-3-hydroxybutyrate derivates disclosed (see para. [0084]). Yang discloses: “There is growing evidence that ketone bodies, which are derived from fatty acid oxidation and usually produced in fasting state or on high-fat diets have broad neuroprotective effects” (see p. 1, abstract). Yang additionally teaches: “In a study with ischemic stroke model, ketone treatment after transient middle cerebral artery (MCA) occlusion enhanced the mitochondrial function, and reduced the oxidative stress, thus reducing the infarct volume, and improving neurological function after ischemic stroke” (see p. 3, bottom left column). Ascertainment of the differences between the prior art and the claims. (See MPEP § 2141.02) There is not a single embodiment in the art of the instantly claimed administration of a therapeutic amount (5 g to 30 g) of free D-BetaHydroxyButyric Acid. Additional limitations will be addressed below. Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) D-betahydroxybutyric acid, structure shown here: PNG media_image1.png 218 331 media_image1.png Greyscale , is part of the metabolism pathway of a family known as ketone bodies. Regarding instant claim 1, it would have been obvious to a skilled artisan to administer the instantly claimed therapeutic amount (and readminister any amount) of free D-betahydroxybutyric acid, particularly to a stroke victim, with a reasonable expectation of success in treatment efficacy and symptom management, as it has been previously demonstrated to be used by the brain and provide cellular energy during a stroke. Additionally, without a finding of unexpected results, free D-betahydroxybutyric acid would be expected to have predictable results to the salt of its conjugate base (3-hydroxybutyrate), where a PHOSITA would reasonably expect a proton to exchange between the two forms in various biochemical environments. Also, the prior art range overlaps with that of the instant therapeutic amount. “In the case where the claimed ranges ’overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists.” MPEP 2144.05(I). Regarding the limitation of “[a]ssessing ketone levels and stroke symptoms” and “[e]valuating the stroke symptoms of a subject in need” of instant claim 1, both would have been obvious to a skilled artisan because ketone bodies were neuroprotective after a stroke and prior to administration; it would be valuable to know the ketone level in the subject in need to determine an appropriate therapeutic amount. Stroke symptoms would be valuable to assess and evaluate because treatment would also be dependent on such states. Consequently, claims 1-2 would have been obvious to a skilled artisan. Regarding instant claim 3, both the “ischemia” and “spinal cord trauma” of the prior art embrace spinal ischemia. A skilled artisan would have a reasonable expectation of success in assessing spinal ischemia symptoms and also administering a therapeutic amount of free D-betahydroxybutyric acid as ketone bodies were previously demonstrated to successfully treat spinal disorders. Claim(s) 4-10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cahill (Annu. Rev. Nutr. 2006, 26: 1-22- disclosed on 12/29/2023 IDS), in view of Veech et al. (US20060280721) and Yang et al. (frontiers in Neurology, 2019, 10: 585, 1-11), as applied to claims 1-3 above, and further in view of Lees et al. (Stroke, 47, 2016, 2373-2379). **The 103 rejection of claims 1-3 over Cahill, in view of Veech and Yang, is incorporated herein by reference. Determining the scope and contents of the prior art. (See MPEP § 2141.01) Cahill, Veech and Yang fail to disclose a therapeutic amount of stroke related therapeutic substances as a co-adjuvant simultaneously delivered with the free D-BetaHydroxyButyric Acid. Lees teaches the following: “Treatment with intravenous alteplase initiated within 4.5 hours of stroke onset increases the chance of achieving an improved level of function for all patients across the age spectrum….” (see “Conclusions” p. 2373). Ascertainment of the differences between the prior art and the claims. (See MPEP § 2141.02) There is not a single embodiment in the prior art of administering both free D-BetaHydroxyButyric acid with alteplase (stroke related therapeutic substance). Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) Regarding instant claims 4-6 and 9, it would have been obvious to administer both alteplase (a stroke related therapeutic substance) with free D-BetaHydroxyButyric Acid either simultaneously or at different time intervals as a result of routine experimentation, as both were known to aid stroke victims. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072. See MPEP 2144.06(I). A skilled artisan would have been motivated to enhance stroke treatment with the combination of the two treatments. Specifically, regarding the limitation “dosing a therapeutic amount” of instant claims 4-6 and “physiologically therapeutic amount” of instant claim 9, the instant claims are not drawn to any specific amount so any amount of alteplase would be sufficient. Regarding instant claims 7, 8, and 10, a PHOSITA would have been motivated to continue treatment and readministering free D-BetaHydroxyButyric Acid to improve treatment outcome with a reasonable expectation of success in stroke symptom management. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626 /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Dec 29, 2023
Application Filed
Aug 20, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790296
DRG-MDM2-3 FOR USE AS A NOVEL MOUSE DOUBLE MINUTE 2 (MDM2) INHIBITOR
4y 2m to grant Granted Nov 10, 2026
Patent 12790352
2,6,9-TRISUBSTITUTED PURINES
2y 11m to grant Granted Nov 10, 2026
Patent 12790342
PHARMACEUTICALLY ACCEPTABLE SALT OF MOR RECEPTOR AGONIST, AND POLYMORPH THEREOF AND USE THEREOF
2y 10m to grant Granted Nov 10, 2026
Patent 12778939
IRAK4 Inhibitors and Topical Uses Thereof
3y 11m to grant Granted Nov 03, 2026
Patent 12767659
TETRACYCLIC DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE
3y 8m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+36.8%)
Low
PTA Risk
Based on 144 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month